Market Research Report
Myasthenia Gravis: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics, H2 2019
|Published by||GervanoRA Data Services LLP||Product code||920043|
|Published||Content info||151 Pages
Delivery time: 1-2 business days
|Myasthenia Gravis: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics, H2 2019|
|Published: January 3, 2020||Content info: 151 Pages||
GervanoRA's pipeline analysis and opportunity assessment report "Myasthenia Gravis: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analytics, H2 2019" analyzed and assessed Myasthenia Gravis pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Myasthenia Gravis industry.
The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Myasthenia Gravis area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Myasthenia Gravis industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Drug Class, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Stage of development, Pipeline Analytics by Target and Pipeline Analytics by Companies.
Our comprehensive analysis on the Myasthenia Gravis drug pipeline identified a total of 29 drug candidates undergoing different stages of development- from Early R&D to Phase 3 stage. Among these, seven molecules are in the Phase 3 stage of development, seven molecules are in Phase 2, two molecules are in Phase 1 and a total of 13 molecules are in non clinical stage of development. We have also identified six drug molecules which have been discontinued or terminated due to various reasons from further development for Myasthenia Gravis.
The report has covered more than 25 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 14 Emerging companies in the domain and hence deriving the key leader.
Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:
Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.